Stereotaxis has announced that it recently received European CE-mark approval for the MAGiC ablation catheter. A press release highlights this approval is a “significant milestone” for Stereotaxis and for the community of physicians pioneering robotics in electrophysiology—and one that is reflective of the company’s commitment to advancing significant innovations that make robotics increasingly impactful across interventional medicine.
Stereotaxis’ MAGiC catheter is a robotically navigated magnetic ablation catheter designed to perform cardiac ablation procedures for treating heart arrhythmias. According to the company, it was developed based on insights collected over the course of nearly 20 years and 150,000 robotic ablation procedures performed using predecessor catheters.
The MAGiC catheter is designed to enhance treatment precision and control during cardiac ablation, while maintaining the intrinsic safety advantage of a soft flexible catheter. Stereotaxis claims that it builds upon existing benefits of robotic cardiac ablation with design enhancements that include:
- Optimised navigation, force and stability—the unique placement of magnets and design of the distal section of the catheter supports intuitive navigation, consistent contact forces, and enhanced stability
- Improved data and information—MAGiC is available with iConnect and the eContact module, offering catheter tissue contact information as well as clear electrogram and responsive temperature data to support physician decision-making
- Efficient, low-flow, uniform cooling—cooling of the tip is accomplished with low-flow irrigation that substantially reduces overall fluid load on patients while protecting against char and coagulation
The MAGiC catheter has been approved in Europe with a broad label that includes the delivery of “local lesions in cardiac tissue for the treatment of cardiac arrhythmias”, according to Stereotaxis’ recent release. The company also notes that clinical experience with MAGiC in an ongoing study in Europe supports expectations for “broad adoption” of MAGiC across robotic users.
“We are thrilled to announce this significant milestone and introduce the MAGiC catheter to European physicians and patients,” said David Fischel, Stereotaxis chairman and chief executive officer (CEO). “We want to thank and recognise the significant contributions from clinicians who guided us throughout the development efforts, and team members of Stereotaxis and Osypka that made this possible. We look forward to seeing MAGiC serve as one of the key pillars in our effort to make robotics broadly impactful and beneficial in electrophysiology, and endovascular surgery.”
